GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy

Table 3 Univariate analysis of 3-year survival

		LRC (%)	p	DMFS (%)	p	DFS (%)	p	DSS (%)	p	OS (%)	p
Stage	I-II III-IV	81.8 66.4	0.245	84.6 77.5	0.548	69.2 55.1	0.282	76.9 60.4	0.208	76.9 54.2	0.033
T stage	T1-2 T3-4	77.5 61.6	0.145	81.9 75.6	0.458	66.3 49.6	0.139	71.3 55.9	0.144	66.7 50.4	0.021
N stage	N0-1 N2-3	74.1 62.2	0.196	87.5 66.8	0.023	66.7 45.8	0.024	75.8 46.6	0.007	72.3 40.0	0.002
Depth (millimeters)	≤10 > 10	61.2 74.8	0.367	90.0 71.7	0.118	55.1 58.8	0.938	67.9 60.3	0.694	62.4 55.1	0.417
Differentiation	Well Moderate Poor	72.0 67.1 75.0	0.818	86.6 82.5 37.5	0.003	66.0 56.6 37.5	0.264	70.2 64.1 37.5	0.203	66.7 56.8 37.5	0.580
Nodal ECS	No Yes	78.1 53.8	0.049	87.9 63.7	0.019	70.7 38.3	0.005	79.5 39.4	0.001	75.6 34.3	0.001
Skin invasion	No Yes	71.6 41.7	0.153	81.3 51.4	0.076	60.5 28.6	0.071	67.0 28.6	0.033	60.8 28.6	0.204
Bone invasion	No Yes	71.6 62.7	0.407	74.5 90.7	0.226	57.7 56.9	0.871	64.2 60.2	0.940	58.9 54.8	0.251
Perineural invasion	No Yes	68.1 71.9	0.717	81.3 69.2	0.295	58.6 51.9	0.349	67.8 50.0	0.170	62.0 45.8	0.318
Blood vessel invasion	No Yes	67.5 80.0	0.729	78.0 75.0	0.999	56.0 60.0	0.891	62.4 60.0	0.909	56.6 60.0	0.741
Lymphatic vessel invasion	No Yes	67.6 75.8	0.845	81.9 55.6	0.014	58.1 46.3	0.218	65.1 45.8	0.106	59.6 41.7	0.117
Margin status (millimeters)	≥ 5 < 5	67.1 80.8	0.406	77.3 84.6	0.737	55.4 68.4	0.517	59.2 83.3	0.152	54.1 65.9	0.157
Concurrent chemotherapy	No Yes	70.8 67.8	0.613	89.3 66.0	0.014	65.2 48.9	0.071	72.6 52.4	0.506	70.6 44.3	0.022
GP96 overexpression	No Yes	90.2 58.7	0.008	95.8 69.5	0.018	86.5 44.7	0.001	95.7 49.0	0.001	87.5 44.9	0.003

Abbreviation: LRC = locoregional control; DMFS = distant metastasis-free survival; DFS = disease-free survival; DSS = disease-specific survival; OS = overall-survival; ECS = extra-capsular spreading.

ISSN: 1748-717X